Dr. Tyrone C. Malloy: Diabetes

Endocrinology-

Diabetes                                  A Phase 3 randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of XXXXXX administered orally, once daily over 24 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control despite treatment with metformin alone or metformin in combination with sulfonylurea

                                                Principal Investigator Dr. Tyrone C. Malloy: Diabetes

                                                Sponsor: Boehringer Ingelheim 

A Phase 3 randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of XXXXXX and sitagliptin administered orally over 24 weeks, in drug naive patients with type 2 diabetes mellitus and insufficient glycemic control despite diet and exercise

                                                Principal Investigator Dr. Tyrone C. Malloy: Diabetes

                                                Sponsor: Boehringer Ingelheim